FIELD: medicine.
SUBSTANCE: group of inventions relates to a method of treating or preventing a disease associated with HPV, and to a composition containing modified immune cells for treating or preventing a disease associated with HPV. Modified immune cells include peripheral blood mononuclear cells and contain HPV antigen and an adjuvant. The HPV antigen is not a full length protein. The HPV antigen and/or adjuvant is intracellularly delivered to incoming immune cells to produce modified immune cells by passing the incoming immune cells through a cell-deforming constriction that causes perturbations of the incoming immune cells.
EFFECT: implementation of the group of inventions ensures the induction of a strong T-cell response to HPV antigens.
131 cl, 51 dwg, 30 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTRACELLULAR DELIVERY OF BIOMOLECULES FOR IMMUNE RESPONSE MODULATION | 2019 |
|
RU2819143C2 |
| DELIVERY OF BIOMOLECULES INTO CELLS OF IMMUNE SYSTEM | 2015 |
|
RU2739794C2 |
| CPG-OLIGONUCLEOTIDE ANALOGUES, CONTAINING HYDROPHOBIC T-ANALOGUES WITH AMPLIFIED IMMUNOSTIMULATORY ACTIVITY | 2007 |
|
RU2477315C2 |
| IMMUNOSTIMULATING PHOSPHOROTHIOATE CpG-OLIGONUCLEOTIDES, CONTAINING PHOSPHODIESTER LINKS, METHOD OF IMMUNOMODULATION, METHOD OF IMMUNE RESPONSE STIMULATION | 2003 |
|
RU2338750C2 |
| COMPOSITIONS AND METHODS FOR PRODUCING T-CELLS | 2018 |
|
RU2793344C2 |
| IMMUNOGENIC COMPOSITION BASED ON RECOMBINANT PROTEINS E6-CBD AND E7-CBD FOR THE TREATMENT OF MALIGNANT NEOPLASMS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS TYPE 16 | 2023 |
|
RU2805482C1 |
| RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMA VIRUS EPITOPES, PROTEIN EMBEDDED ADENYLATECYCLASE OR ITS FRAGMENT, ITS THERAPEUTIC APPLICATION | 2005 |
|
RU2441022C2 |
| IMMUNOSTIMULATORY OLIGONUCLEOTIDES | 2012 |
|
RU2610690C2 |
| VACCINE CONTAINING RIBOSOMAL PROTEIN EXTRACT (RPE) AND Th1-ACTIVATING ADJUVANT | 2009 |
|
RU2521499C2 |
| SURVIVIN PEPTIDE VACCINE | 2006 |
|
RU2396088C2 |
